Ignite Creation Date:
2024-05-06 @ 12:22 PM
Last Modification Date:
2024-10-26 @ 12:58 PM
Study NCT ID:
NCT03747029
Status:
COMPLETED
Last Update Posted:
2021-02-09
First Post:
2018-11-16
Brief Title:
Serum Calcium to Phosphorous CaP Ratio in the Diagnosis of Ca-P Metabolism Disorders a Multicentre Study
Sponsor:
Azienda Ospedaliero-Universitaria di Modena
Organization:
Azienda Ospedaliero-Universitaria di Modena
Study Overview
Official Title:
Serum Calcium to Phosphorous CaP Ratio in the Diagnosis of Ca-P Metabolism Disorders a Multicentre Study
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary hyperparathyroidism PHPT and Hypoparathyroidism HP are two of the most frequent disorder of Calcium-Phosphorus Ca-P metabolism The CaP ratio is an accurate tool to differentiate patients with PHPT from healthy subjects according to a previous single-centre study The reliability of this index is based on the fact that serum Ca and P are inversely related together either in healthy subjects or in patients with PHPT and HP
Detailed Description:
The aim of this study is to investigate the accuracy and diagnostic value of CaP ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism The definition of a valid cut-off of serum CaP ratio for patients with these disorders will be of help especially in those patients with apparently normal biochemical profile but suggestive for primary hyperparathyroidism and hypoparathyroidism
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None